MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”),
today announced operating and financial results for the fourth
quarter and full year 2023.
Recent Operating and Financial Highlights:
- Fourth quarter and full year 2023
net sales of $87 million and $321 million, reflecting 17%
and 20% year-over-year growth, respectively.
- GAAP Net Income for the fourth
quarter and full year 2023 of $53 million and
$58 million, respectively. GAAP Net income margin for the
fourth quarter and full year 2023 were also 62% and 18%,
respectively.
- Adjusted EBITDA1 and Adjusted EBITDA
Margin for the fourth quarter 2023 of $21 million and 24%,
respectively.
- Launched EPIEFFECT®, the latest
addition to the Company’s broad portfolio of Advanced Wound Care
products.
- Announced conversion of outstanding
Series B convertible preferred stock to common stock.
- Announced new senior secured credit
facilities and debt refinancing in January 2024 and repaid $30
million revolving credit facility portion with cash on hand earlier
this week.
Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "We
are once again pleased to report on another impressive quarter of
top-line growth, profitability and cash flow generation as we
closed out a transformative 2023, driven by the improved alignment
and focus of the Company. Moreover, the 20% top-line growth we
achieved for the full-year 2023 exceeded expectations and provides
solid momentum going forward. Additionally, in a very short period
of time, the team has successfully unlocked robust cash flow
generation that should continue to improve with scale over
time."
Mr. Capper continued, "Given the commercial strength of the
organization, we expect 2024 to be another noteworthy year with low
double-digit net sales percentage growth and Adjusted EBITDA margin
above 20%. Our improved cash flow generation and balance sheet
enhancements also provide the necessary support to accelerate our
growth plan as we capitalize on the opportunities before us."
_________________________
1 Adjusted EBITDA and related margins, Adjusted Net Income and
Adjusted EPS are non-GAAP financial measures. See “Reconciliation
of Non-GAAP Measures” for a reconciliation of Adjusted EBITDA and
Adjusted Net Income to Net income (loss) and Adjusted EPS to
Diluted earnings per share, located in “Selected Unaudited
Financial Information” of this release.
|
Three Months Ended December 31, |
|
Year Ended December 31, |
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
Net Income (loss) |
$ |
53,476 |
|
|
$ |
(415 |
) |
|
$ |
58,228 |
|
|
$ |
(30,197 |
) |
Non-GAAP Adjustments: |
|
|
|
|
|
|
|
Depreciation expense |
|
611 |
|
|
|
796 |
|
|
|
2,665 |
|
|
|
3,345 |
|
Amortization of intangible assets |
|
192 |
|
|
|
182 |
|
|
|
762 |
|
|
|
701 |
|
Interest expense, net |
|
1,593 |
|
|
|
1,450 |
|
|
|
6,457 |
|
|
|
5,016 |
|
Income tax provision (benefit) expense |
|
(40,349 |
) |
|
|
28 |
|
|
|
(39,780 |
) |
|
|
206 |
|
Investigation, restatement and related expenses |
|
524 |
|
|
|
3,406 |
|
|
|
5,176 |
|
|
|
12,177 |
|
Share-based compensation |
|
4,385 |
|
|
|
1,868 |
|
|
|
17,178 |
|
|
|
12,666 |
|
Expenses related to disbanding of Regenerative Medicine business
unit |
|
785 |
|
|
|
— |
|
|
|
6,384 |
|
|
|
— |
|
Reorganization expenses |
|
— |
|
|
|
— |
|
|
|
1,412 |
|
|
|
3,105 |
|
Adjusted EBITDA |
$ |
21,217 |
|
|
$ |
7,315 |
|
|
$ |
58,482 |
|
|
$ |
7,019 |
|
Adjusted EBITDA margin |
|
24.4 |
% |
|
|
9.8 |
% |
|
|
18.2 |
% |
|
|
2.6 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fourth Quarter and Full Year 2023 Results
Discussion2
Net Sales
MIMEDX reported net sales for the three months ended December
31, 2023, of $87 million, compared to $74 million for the
three months ended December 31, 2022, an increase of 17%. Net sales
growth came from solid contributions in both the Wound &
Surgical end markets and across each of our main sites of
service.
For the full year 2023, MIMEDX reported net sales of
$321 million, compared to $268 million in the prior year
period, reflecting growth of 20%, which was also driven by a
combination of contributions in Wound & Surgical and across our
sites of service.
_________________________2 The following discussion of the
Company's fourth quarter and full year 2023 results are made on a
"continuing operations basis" and exclude the historical costs of
the Regenerative Medicine business unit, which was disbanded
beginning in June 2023. For a full discussion of the impact of
these discontinued operations, please refer to our Annual Report on
Form 10-K filed with the Securities and Exchange Commission for the
year ended December 31, 2023.
Gross Profit and Margin
Gross profit for the three months ended December 31, 2023, was
$73 million, an increase of $13 million as compared to
the prior year period. Gross margin for the three months ended
December 31, 2023 was 84.1%, compared to 80.7% in the prior year
period. The year-over-year improvement in gross margin was driven
by favorable product mix and our continued execution on yield
improvement projects.
For the full year 2023, gross profit was $267 million,
reflecting an increase of $47 million compared to the prior
year period. Additionally, gross margin for the full year 2023 was
83.0%, compared to 82.0% for the full year 2022 and the improvement
was also driven by improved yields and a favorable product mix.
Operating Expenses
Selling, general and administrative ("SG&A") expenses for
the three months ended December 31, 2023, were $54 million
compared to $50 million for the three months ended December
31, 2022. SG&A expense during the fourth quarter 2023 included
increased sales commissions due to higher sales volumes.
For the full year 2023, SG&A expenses totaled
$211 million, compared to $209 million for the prior year
period, reflecting year over year growth of 1.1%. The increase was
driven by higher levels of sales commissions due to higher sales
volumes, as well as increases in stock-based compensation in 2023.
These increases were partially offset by a decrease in professional
services related to certain administrative expenses, including
severance expenses associated with the departure of our former CEO
in 2022.
Research and development expenses were $2 million for the
three months ended December 31, 2023, compared to $3 million
for the three months ended December 31, 2022. For the full year
2023, research and development expenses remained essentially flat
at $13 million compared to 2022. Our R&D expenses in 2022
and 2023 were primarily driven by the development and launches of
our newest products in the portfolio - AMNIOEFFECT, AXIOFILL and
EPIEFFECT - along with additional early-stage Wound & Surgical
products in development.
Investigation, restatement and related expense for the three
months ended December 31, 2023 was $1 million, compared to
$3 million for the three months ended December 31, 2022. For
the full year 2023, investigation, restatement and related expenses
totaled $5 million compared to $12 million in 2022. The
decrease was related to negotiated reductions in legal fees
previously incurred. In addition, following the end of a legal
proceeding, expenses under our last material proceeding involving
indemnification of former officers and directors substantially
ceased in 2023.
Net income from continuing operations for the three months and
full year ended December 31, 2023, were $51 million and
$67 million, respectively, compared to a net income from
continuing operations of $2 million for the three months ended
December 31, 2022 and a net loss from continuing operations of
$20 million for the year ended December 31, 2022. Net income
from continuing operations for the three months and full year ended
December 31, 2023 were positively impacted by a $37 million
income tax provision benefit, reflecting a non-cash reversal of a
valuation allowance that was previously recorded against the
deferred tax asset balance. The reversal was a result of an
analysis following the Company's conclusion that the Company's
disbanded Regenerative Medicine segment qualified as a discontinued
operation, in concert with the Company’s operating results.
Cash and Cash Equivalents
As of December 31, 2023, the Company had $82 million of
cash and cash equivalents compared to $66 million as of
December 31, 2022 and $81 million as of September 30, 2023.
The increase during the year ended December 31, 2023 was primarily
a result of year-over-year increases in net sales, which drove
increases in collections from customers, as well as year-over-year
decreases in operating expenses, partially offset by the $9.5
million repurchase of a portion of the shares of Series B
Convertible Preferred Stock, held by certain funds managed by
Hayfin Capital Management, LLP in October 2023.
Financial Goals
The Company's goal is to deliver net sales percentage growth in
the low double-digits annually.
In 2024, the Company expects to see continued growth in both the
Wound and Surgical end markets, despite more difficult prior year
growth comparisons. In particular, the Company continues to
anticipate solid growth in the private office setting driven by the
recent launch of EPIEFFECT and ongoing changes in purchasing
behaviors related to Medicare reimbursement. Additionally, the
Company expects to continue to drive growth across a variety of
Surgical use cases as the body of evidence for utilization of its
Surgical products, such as AMNIOEFFECT, continues to grow.
For the full year 2024, the Company expects its Adjusted EBITDA
as a percent of net sales to be above 20%.
Conference Call and Webcast
MIMEDX will host a conference call and webcast to review its
fourth quarter and full year 2023 results on Wednesday, February
28, 2024, beginning at 4:30 p.m., Eastern Time. The call can be
accessed using the following information:
Webcast: Click here U.S. Investors:
877-407-6184International Investors: 201-389-0877Conference ID:
13743067
A replay of the webcast will be available for approximately 30
days on the Company’s website at www.mimedx.com following the
conclusion of the event.
Important Cautionary Statement
This press release includes forward-looking statements.
Statements regarding: (i) future sales or sales growth; (ii) our
2024 financial goals and expectations for future financial results,
including levels of net sales, Adjusted EBITDA, and Adjusted EBITDA
margin; (iii) our cash flows; (iv)our expectations regarding the
use of our products, including EPIEFFECT and AMNIOEFFECT; and (v)
continued growth in different care settings. Additional
forward-looking statements may be identified by words such as
"believe," "expect," "may," "plan," “goal,” “outlook,” "potential,"
"will," "preliminary," and similar expressions, and are based on
management's current beliefs and expectations.
Forward-looking statements are subject to risks and
uncertainties, and the Company cautions investors against placing
undue reliance on such statements. Actual results may differ
materially from those set forth in the forward-looking statements.
Factors that could cause actual results to differ from expectations
include: (i) future sales are uncertain and are affected by
competition, access to customers, patient access to healthcare
providers, the reimbursement environment and many other factors;
(ii) the Company may change its plans due to unforeseen
circumstances; (iii) the results of scientific research are
uncertain and may have little or no value; (iv) our ability to sell
our products in other countries depends on a number of factors
including adequate levels of reimbursement, market acceptance of
novel therapies, and our ability to build and manage a direct sales
force or third party distribution relationship; (v) the
effectiveness of amniotic tissue as a therapy for particular
indications or conditions is the subject of further scientific and
clinical studies; and (vi) we may alter the timing and amount of
planned expenditures for research and development based on
regulatory developments. The Company describes additional risks and
uncertainties in the Risk Factors section of its most recent annual
report and quarterly reports filed with the Securities and Exchange
Commission. Any forward-looking statements speak only as of the
date of this press release and the Company assumes no obligation to
update any forward-looking statement.
About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal.
With more than a decade of helping clinicians manage chronic and
other hard-to-heal wounds, MIMEDX is dedicated to providing a
leading portfolio of products for applications in the wound care,
burn, and surgical sectors of healthcare. The Company’s vision is
to be the leading global provider of healing solutions through
relentless innovation to restore quality of life. For additional
information, please visit www.mimedx.com.
Contact:Matt NotarianniInvestor
Relations470.304.7291mnotarianni@mimedx.com
Selected Unaudited Financial Information
MiMedx Group, Inc. |
Condensed Consolidated Balance Sheets |
(in thousands) Unaudited |
|
December 31, 2023 |
|
December 31, 2022 |
ASSETS |
|
|
|
Current assets: |
|
|
|
Cash and cash equivalents |
$ |
82,000 |
|
$ |
65,950 |
|
Accounts receivable, net |
|
53,871 |
|
|
43,084 |
|
Inventory |
|
21,021 |
|
|
13,183 |
|
Prepaid expenses |
|
5,624 |
|
|
7,315 |
|
Current assets of discontinued operations |
|
— |
|
|
1,331 |
|
Other current assets |
|
1,745 |
|
|
3,335 |
|
Total current assets |
|
164,261 |
|
|
134,198 |
|
Property and equipment, net |
|
6,974 |
|
|
7,856 |
|
Right of use asset |
|
2,132 |
|
|
3,400 |
|
Goodwill |
|
19,441 |
|
|
19,441 |
|
Intangible assets, net |
|
5,257 |
|
|
5,852 |
|
Deferred tax asset |
|
40,777 |
|
|
— |
|
Other assets |
|
205 |
|
|
148 |
|
Noncurrent assets of discontinued operations |
|
— |
|
|
535 |
|
Total assets |
$ |
239,047 |
|
$ |
171,430 |
|
LIABILITIES, CONVERTIBLE
PREFERRED STOCK, AND STOCKHOLDERS’ EQUITY (DEFICIT) |
|
|
|
Current liabilities: |
|
|
|
Accounts payable |
$ |
9,048 |
|
$ |
8,454 |
|
Accrued compensation |
|
22,353 |
|
|
20,856 |
|
Accrued expenses |
|
9,361 |
|
|
10,934 |
|
Current liabilities of discontinued operations |
|
1,352 |
|
|
1,479 |
|
Other current liabilities |
|
3,894 |
|
|
1,834 |
|
Total current liabilities |
|
46,008 |
|
|
43,557 |
|
Long term debt, net |
|
48,099 |
|
|
48,594 |
|
Other liabilities |
|
2,223 |
|
|
4,773 |
|
Total liabilities |
|
96,330 |
|
|
96,924 |
|
Convertible preferred
stock |
|
— |
|
|
92,494 |
|
Total stockholders' equity
(deficit) |
|
142,717 |
|
|
(17,988 |
) |
Total liabilities, convertible
preferred stock, and stockholders’ equity (deficit) |
$ |
239,047 |
|
$ |
171,430 |
|
|
|
|
|
MiMedx Group, Inc. |
Condensed Consolidated Statements of
Operations |
(in thousands, except share and per share amounts) Unaudited |
|
Three Months Ended December 31, |
|
Year Ended December 31, |
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
Net sales |
$ |
86,832 |
|
|
$ |
74,375 |
|
|
$ |
321,477 |
|
|
$ |
267,841 |
|
Cost of sales |
|
13,841 |
|
|
|
14,369 |
|
|
|
54,634 |
|
|
|
48,316 |
|
Gross profit |
|
72,991 |
|
|
|
60,006 |
|
|
|
266,843 |
|
|
|
219,525 |
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
Selling, general and administrative |
|
54,352 |
|
|
|
49,922 |
|
|
|
211,124 |
|
|
|
208,673 |
|
Research and development |
|
2,434 |
|
|
|
2,955 |
|
|
|
12,665 |
|
|
|
12,701 |
|
Investigation, restatement and related |
|
524 |
|
|
|
3,406 |
|
|
|
5,176 |
|
|
|
12,177 |
|
Amortization of intangible assets |
|
192 |
|
|
|
182 |
|
|
|
762 |
|
|
|
701 |
|
Operating income (loss) |
|
15,489 |
|
|
|
3,541 |
|
|
|
37,116 |
|
|
|
(14,727 |
) |
|
|
|
|
|
|
|
|
Other expense, net |
|
|
|
|
|
|
|
Interest expense, net |
|
(1,593 |
) |
|
|
(1,450 |
) |
|
|
(6,457 |
) |
|
|
(5,016 |
) |
Other income (expense), net |
|
16 |
|
|
|
(3 |
) |
|
|
(26 |
) |
|
|
(4 |
) |
Income (loss) from continuing
operations before income tax provision |
|
13,912 |
|
|
|
2,088 |
|
|
|
30,633 |
|
|
|
(19,747 |
) |
Income tax provision benefit
(expense) |
|
37,375 |
|
|
|
(28 |
) |
|
|
36,806 |
|
|
|
(206 |
) |
Net income (loss) from
continuing operations |
$ |
51,287 |
|
|
$ |
2,060 |
|
|
$ |
67,439 |
|
|
$ |
(19,953 |
) |
Income (loss) from
discontinued operations, net of tax |
|
2,189 |
|
|
|
(2,475 |
) |
|
|
(9,211 |
) |
|
|
(10,244 |
) |
Net income (loss) |
$ |
53,476 |
|
|
$ |
(415 |
) |
|
$ |
58,228 |
|
|
$ |
(30,197 |
) |
|
|
|
|
|
|
|
|
Net income (loss) from
continuing operations available to common shareholders |
$ |
44,829 |
|
|
$ |
390 |
|
|
$ |
55,796 |
|
|
$ |
(26,533 |
) |
|
|
|
|
|
|
|
|
Basic net income (loss) per
common share: |
|
|
|
|
|
|
|
Continuing operations |
$ |
0.38 |
|
|
$ |
0.00 |
|
|
$ |
0.48 |
|
|
$ |
(0.24 |
) |
Discontinued operations |
$ |
0.02 |
|
|
$ |
(0.02 |
) |
|
$ |
(0.08 |
) |
|
$ |
(0.09 |
) |
Basic net income (loss) per
common share: |
$ |
0.40 |
|
|
$ |
(0.02 |
) |
|
$ |
0.40 |
|
|
$ |
(0.33 |
) |
|
|
|
|
|
|
|
|
Diluted net income (loss) per
common share: |
|
|
|
|
|
|
|
Continuing operations |
$ |
0.31 |
|
|
$ |
0.00 |
|
|
$ |
0.43 |
|
|
$ |
(0.24 |
) |
Discontinued operations |
$ |
0.01 |
|
|
$ |
(0.02 |
) |
|
$ |
(0.06 |
) |
|
$ |
(0.09 |
) |
Diluted net income (loss) per
common share: |
$ |
0.32 |
|
|
$ |
(0.02 |
) |
|
$ |
0.37 |
|
|
$ |
(0.33 |
) |
|
|
|
|
|
|
|
|
Weighted average common shares
outstanding - basic |
|
119,367,482 |
|
|
|
113,676,496 |
|
|
|
116,495,810 |
|
|
|
112,909,266 |
|
Weighted average common shares
outstanding - diluted |
|
148,076,079 |
|
|
|
114,233,567 |
|
|
|
145,962,462 |
|
|
|
112,909,266 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
MiMedx Group, Inc. |
Condensed Consolidated Statements of Cash
Flows |
(in thousands) Unaudited |
|
Three Months Ended December 31, |
|
Year Ended December 31, |
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
Net cash flows provided by
(used in) operating activities |
|
10,257 |
|
|
|
(5,624 |
) |
|
|
26,775 |
|
|
|
(17,893 |
) |
Net cash flows used in
investing activities |
|
(481 |
) |
|
|
(1,709 |
) |
|
|
(2,155 |
) |
|
|
(2,660 |
) |
Net cash flows used in
financing activities |
|
(8,940 |
) |
|
|
66 |
|
|
|
(8,570 |
) |
|
|
(580 |
) |
Net change in cash |
$ |
836 |
|
|
$ |
(7,267 |
) |
|
$ |
16,050 |
|
|
$ |
(21,133 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of Non-GAAP Measures
In addition to our GAAP results, we provide certain non-GAAP
metrics including Adjusted EBITDA, related margins, Free Cash Flow,
Adjusted Net Income, and Adjusted Earnings Per Share ("Adjusted
EPS"). We believe that the presentation of these measures provides
important supplemental information to management and investors
regarding our performance. These measurements are not a substitute
for GAAP measurements. Company management uses these Non-GAAP
measurements as aids in monitoring our ongoing financial
performance from quarter-to-quarter and year-to-year on a regular
basis and for benchmarking against comparable companies.
These non-GAAP financial measures reflect the exclusion of the
following items:
- Share-based compensation expense -
expense recognized related to awards to various employees pursuant
to our share-based compensation plans. This expense is reflected
amongst cost of sales, research and development expense, and
selling, general, and administrative expense in the unaudited
condensed consolidated statements of operations. Refer to Note 11,
Equity, in our Form 10-K for the year ended December 31, 2023 for
details.
- Investigation, restatement, and
related (benefit) expense - expenses incurred toward the legal
defense of certain former officers and directors, net of negotiated
reductions and settlements of amounts previously advanced. This
expense is reflected in the line of the same name in our unaudited
condensed consolidated statements of operations.
- Expenses related to the Disbanding
of Regenerative Medicine - incremental expenses recognized or
incurred directly as a result of our announcement to disband our
Regenerative Medicine segment. This reflects (i) write-downs of
clinical trial assets, (ii) charges associated with the wind-down
of contracts associated with our clinical trial program, (iii)
severance expenses incurred which were directly attributable to the
disbanding, and (iv) impairment of goodwill. Severance expenses are
reflected in research and development expense on the unaudited
condensed consolidated statements of operations. All other charges
are reflected in restructuring expense in the unaudited condensed
consolidated statements of operations.
- Reorganization expense - expenses
incurred toward the realignment of our operating strategy. These
expenses primarily relate to severance expenses related to certain
officers. These expenses are reflected as a component of selling,
general, and administrative expense in the unaudited condensed
consolidated statements of operations.
- Effects of antidilution - reflects
the impact of reflecting certain transactions which are dilutive
for purposes of calculating EPS on a GAAP basis, but are
antidilutive for purposes of calculating Adjusted EPS. For Q4 and
FY 2023, this reflects the adjustment for dividends on the
Company's Series B Preferred Stock to the numerator and incremental
shares which would have been issued if the Series B Preferred Stock
were converted at the beginning of the relevant period, weighted
for the portion of the period that the shares were not converted,
to the denominator. The reflection of this reduced the denominator
by 25.3 million and 27.5 million shares, respectively.
- Income Tax Adjustment - for purposes
of calculating Adjusted Net Income (Loss) and Adjusted Earnings Per
Share, reflects our expectation of a long-term effective tax rate,
which is normalized and balance sheet-agnostic. Actual reporting
tax expense will be based on GAAP earnings, and may differ from the
expected long-term effective tax rate due to a variety of factors,
including the tax treatment of various transactions included in
GAAP net income and other reconciling items that are excluded in
determining Adjusted Net Income (Loss) and Adjusted EPS. The
long-term normalized effective tax rate was 25% for each of the
years ended December 31, 2023 and 2022.
Adjusted EBITDA and Adjusted EBITDA margin
Adjusted EBITDA consists of GAAP net income (loss) excluding:
(i) depreciation, (ii) amortization of intangibles, (iii) interest
expense, net, (iv) income tax provision, (v) investigation,
restatement and related expenses, (vi) reorganization expenses
related to severance charges for certain officers (vii) expenses
related to disbanding of the Regenerative Medicine business unit
and (viii) share-based compensation.
Please refer to the tables at the beginning of this press
release for reconciliation to GAAP net income (loss).
Adjusted Net Income (Loss)
Adjusted Net Income (Loss) provides a view of our operating
performance, exclusive of certain items which are non-recurring or
not reflective of our core operations. Management uses Adjusted Net
Income to assess Company financial performance.
Adjusted Net Income is defined as GAAP net income (loss) plus
(i) investigation restatement and related expenses, (ii) expenses
related to disbanding our Regenerative Medicine business unit,
(iii) reorganization expenses related to severance charges for
certain officers, and (iv) the long-term adjusted effective income
tax rate.
A reconciliation of GAAP Net Income to Adjusted
Net Income appears in the table below (in thousands):
|
Three Months Ended December 31, |
|
Year Ended December 31, |
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
Net income (loss) |
$ |
53,476 |
|
|
$ |
(415 |
) |
|
$ |
58,228 |
|
|
$ |
(30,197 |
) |
Investigation, restatement and
related expenses |
|
524 |
|
|
|
3,406 |
|
|
|
5,176 |
|
|
|
12,177 |
|
Expenses related to disbanding
of Regenerative Medicine business unit |
|
785 |
|
|
|
— |
|
|
|
6,384 |
|
|
|
— |
|
Reorganization expenses |
|
— |
|
|
|
— |
|
|
|
1,412 |
|
|
|
3,105 |
|
Long-term adjusted effective
income tax rate |
|
(43,958 |
) |
|
|
(726 |
) |
|
|
(47,635 |
) |
|
|
3,883 |
|
Adjusted net income
(loss) |
$ |
10,827 |
|
|
$ |
2,265 |
|
|
$ |
23,565 |
|
|
$ |
(11,032 |
) |
|
Adjusted Earnings Per Share
Adjusted Earnings Per Share is intended to provide a normalized
view of earnings per share by removing items that may be irregular,
one-time, or non-recurring from net income. This enables us to
identify underlying trends in our business that could otherwise be
masked by such items. Adjusted Earnings Per Share consists of GAAP
diluted earnings per share including adjustments for: (i) effects
of antidilution, (ii) investigation, restatement and related
expenses, (iii) reorganization expenses related to severance
charges for certain officers and (iv) long-term adjusted effective
income tax rate.
A reconciliation of GAAP diluted earnings per share to Adjusted
Earnings Per Share appears in the table below (per diluted
share):
|
For the Three Months Ended December 31, |
|
For the Year Ended December 31, |
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
GAAP net income (loss) per common share - diluted |
$ |
0.32 |
|
|
$ |
(0.02 |
) |
|
$ |
0.37 |
|
|
$ |
(0.33 |
) |
Effects of antidilution |
$ |
0.07 |
|
|
$ |
0.00 |
|
|
$ |
0.03 |
|
|
$ |
0.00 |
|
Investigation, restatement and related (benefit) expense |
$ |
0.00 |
|
|
$ |
0.03 |
|
|
$ |
0.04 |
|
|
$ |
0.11 |
|
Reorganization expenses |
$ |
0.00 |
|
|
$ |
0.00 |
|
|
$ |
0.01 |
|
|
$ |
0.03 |
|
Expenses related to disbanding of Regenerative Medicine business
unit |
$ |
0.01 |
|
|
$ |
0.00 |
|
|
$ |
0.05 |
|
|
$ |
0.00 |
|
Long-term adjusted effective income tax rate |
$ |
(0.36 |
) |
|
$ |
0.00 |
|
|
$ |
(0.40 |
) |
|
$ |
0.03 |
|
Adjusted Earnings Per Share |
$ |
0.04 |
|
|
$ |
0.01 |
|
|
$ |
0.10 |
|
|
$ |
(0.16 |
) |
Weighted average common shares outstanding - adjusted (in
millions) |
|
122.7 |
|
|
|
114.2 |
|
|
|
118.5 |
|
|
|
112.9 |
|
|
|
|
|
|
|
|
|
Free Cash Flow
Free Cash Flow is intended to provide a measure of our ability
to generate cash in excess of capital investments. It provides
management with a view of cash flows which can be used to finance
operational and strategic investments.
Free Cash Flow is defined as net cash provided by (used in)
operating activities less capital expenditures, including purchases
of equipment.
A reconciliation of GAAP net cash flows provided by (used in)
operating activities to Free Cash Flow appears in the table below
(in thousands):
|
For the Three Months Ended December 31, |
|
For the Year Ended December 31, |
|
|
2023 |
|
|
|
2022 |
|
|
|
2023 |
|
|
|
2022 |
|
Net cash flows provided by
(used in) operating activities |
|
10,257 |
|
|
|
(5,624 |
) |
|
|
26,775 |
|
|
|
(17,893 |
) |
Capital expenditures,
including purchases of equipment |
|
(427 |
) |
|
|
(667 |
) |
|
|
(1,987 |
) |
|
|
(1,514 |
) |
Free Cash Flow |
$ |
9,830 |
|
|
$ |
(6,291 |
) |
|
$ |
24,788 |
|
|
$ |
(19,407 |
) |
MiMedx (NASDAQ:MDXG)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
MiMedx (NASDAQ:MDXG)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024